ArticleAbdominal radiology (New York)2026
A simplified MRI‑based risk score and nomogram to predict initial objective response in unresectable hepatocellular carcinoma treated with HAIC, targeted therapy, and immunotherapy: a multicenter study.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to develop and validate a simplified risk score based on pretreatment Gd‑EOB‑DTPA MRI features for the noninvasive prediction of initial objective response rate (ORR) in patients with unresectable hepatocellular carcinoma (uHCC) undergoing triple therapy (hepatic arterial infusion chemotherapy [HAIC], tyrosine kinase inhibitors, and immune checkpoint inhibitors).
methodsThis retrospective study enrolled 223 uHCC patients from two medical centers who underwent Gd‑EOB‑DTPA‑enhanced MRI prior to initiating triple therapy (training set: n = 127; external test set: n = 96). Imaging features were evaluated and extracted. Independent predictors of initial ORR were identified by multivariate logistic regression to build a simplified imaging risk score (I-score), and a nomogram was constructed to visualize the final predictive model. Model performance was assessed by AUC, calibration (Hosmer‑Lemeshow test), confusion matrix, and decision curve analysis (DCA), with internal bootstrap and external validation. SHAP analysis provided interpretability. Patients were stratified into low‑ and high‑risk groups, and Kaplan‑Meier curves for progression‑free survival (PFS) and overall survival (OS) were compared.
resultsThree MRI features (irregular morphology, rim enhancement, peritumoral low signal) were independent negative predictors of initial ORR. The simplified I-score was formulated as: 1×(irregular morphology) + 1 × (rim enhancement) + 2 × (peritumoral low signal), with an optimal cut-off of 1.5. Following LASSO regression, BMI > 22.55, PA < 182.5 mg/L, NLR > 2.37, and I-score ≥ 2 were included in the nomogram. The nomogram achieved AUCs of 0.890 in training and 0.841 in validation for ORR prediction, demonstrating good calibration (P > 0.05) and clinical benefit. SHAP analysis identified I-score as the most important contributor. The model significantly outperformed BCLC, ALBI, Child‑Pugh, and Six‑and‑Twelve staging systems (all P < 0.05). High‑risk patients had significantly worse PFS and OS than low‑risk patients.
conclusionThe MRI‑based simplified risk score and the derived nomogram offer a noninvasive and precise method for predicting initial ORR and classifying prognosis in uHCC patients undergoing triple therapy.
Indexed as
Identifiers
42579007What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.